Directorate Change
Oxford BioDynamics Plc announced that Stephen Diggle has stepped down as a Director, having served as Non-Executive Director since October 2016. Vulpes Investment Management, controlled by Diggle, remains the company's largest shareholder and will nominate a new non-executive director. The company thanked Diggle for his support and wisdom over his tenure.
Select text to share a quote on X · sign in to keep highlights & notes in your OBD notes
Oxford, UK - 26 January 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, confirms that Stephen Diggle has stepped down as a Director of the Company with effect from today.
As set out in the announcement of the Company's results on 16 December 2025, after serving as Non-Executive Director for nine years, in line with good practice Steve indicated his intention to stand down from the Board in advance of the AGM to be held today.
Vulpes Investment Management, which is controlled by Steve, remains the Company's largest shareholder through the Vulpes Testudo Fund and the Vulpes Life Sciences Fund, and will nominate a new non-executive director in due course.
Executive Chairman Iain Ross said: "Steve has served on the Board as a Non-Executive Director since October 2016, prior to the Company's listing on AIM later that year. On behalf of the whole Board, I would again like to thank Steve for his support and wisdom over this long period and particularly to me since my appointment early in 2025."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.